Vyant Bio : Skyline Signature Series Presentation

H U M A N - P O W E R E D D R U G D I S C O V E R Y

Nasdaq: VYNT

Skyline Signature Series

Thursday, September 8, 2022 - 12:00pm ET

Leadership Team Introductions

Jay Roberts, MBA

Chief Executive Officer

30+ years healthcare executive leader

50+ capital markets and M&A transactions

17 years in public company leadership roles with multiple premium exits

Andy LaFrence, CPA

Chief Financial Officer

KPMG Audit Partner & IPO Readiness Practice

Ten years of operational CFO experience, including 5 years public company

36 years providing financial and business strategy

Robert T. Fremeau, Jr. PhD

Chief Scientific Officer

20+ years in drug discovery with experience in industry and academia with multiple novel candidates across neuro disease indications

Expertise in small molecule hit-to-lead and lead optimization

PhD Biochemistry

Postdoc training in molecular neuroscience

Nasdaq: VYNT

2

S A F E H A R B O R

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that exist in our operations and business environment, which may be beyond our control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward- looking statements. For example, forward-looking statements include, without limitation: statements pertaining to Vyant Bio, Inc.'s expectations regarding future financial and/or operating results, the efficacy of our drug screening and discovery process, potential for our services, future revenues or growth and plans, strategies and objectives of management for future operations or transactions. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2021 and any subsequent filings. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, Vyant Bio. Forward-looking statements represent the judgment of the Company's management regarding future events. Although the we believe that the expectations reflected in such forward- looking statements are reasonable at the time that they are made, we can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Company assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

Nasdaq: VYNT	3

DRUG DISCOVERY

Needs a Paradigm Shift

Defines a New Approach

Underperformance of Widely Used Models for Predicting Drug Efficacy and Safety

Late Introduction of Human Biology in the R&D Process Leads to High Failure and Cost

Deep Expertise and Global Presence in Drug

Discovery

Human Biology and Data Science Driven

Proprietary Discovery Engine

Focused on Efficiently Discovering Novel Therapeutics for Neurological Developmental and Degenerative Diseases

Nasdaq: VYNT	4

Rapid and Efficient Drug Discovery Platform

Clinical Biomarker-	Target Identification / Hit Validation	De-Risked Lead
based Discovery	(Human-based Models, Advanced Analytics)	Candidates

Supported by

	Platform Integration
Advanced Analytics	Relevant models	Regulatory
Patient biology, iPSC-derived,
AI, ML, Unbiased	Ready Data
IND-enabling in vivo

Nasdaq: VYNT

5